FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report | Optometry Times - Clinical News

Published on December 16, 2025
Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.
Continue reading on website
Other news

General Optical Council recruiting council associates

December 16, 2025
The two vacancies – one for a DO or CLO, and one for an optometrist – aim to increase the diversity of perspectives represented on council

Dompé enrolls first patients in phase 3 trial of Isocyclosporin for atopic keratoconjunctivitis | Optometry Times - Clinical News

December 16, 2025
Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.